Chromosomal instability: a key driver in glioma pathogenesis and progression.
Chromosomal instability
Gliomas
Molecular genetics
Neuro-oncology
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
04 Sep 2024
04 Sep 2024
Historique:
received:
08
02
2024
accepted:
26
08
2024
medline:
4
9
2024
pubmed:
4
9
2024
entrez:
3
9
2024
Statut:
epublish
Résumé
Chromosomal instability (CIN) is a pivotal factor in gliomas, contributing to their complexity, progression, and therapeutic challenges. CIN, characterized by frequent genomic alterations during mitosis, leads to genetic abnormalities and impacts cellular functions. This instability results from various factors, including replication errors and toxic compounds. While CIN's role is well documented in cancers like ovarian cancer, its implications for gliomas are increasingly recognized. CIN influences glioma progression by affecting key oncological pathways, such as tumor suppressor genes (e.g., TP53), oncogenes (e.g., EGFR), and DNA repair mechanisms. It drives tumor evolution, promotes inflammatory signaling, and affects immune interactions, potentially leading to poor clinical outcomes and treatment resistance. This review examines CIN's impact on gliomas through a narrative approach, analyzing data from PubMed/Medline, EMBASE, the Cochrane Library, and Scopus. It highlights CIN's role across glioma subtypes, from adult glioblastomas and astrocytomas to pediatric oligodendrogliomas and astrocytomas. Key findings include CIN's effect on tumor heterogeneity and its potential as a biomarker for early detection and monitoring. Emerging therapies targeting CIN, such as those modulating tumor mutation burden and DNA damage response pathways, show promise but face challenges. The review underscores the need for integrated therapeutic strategies and improved bioinformatics tools like CINdex to advance understanding and treatment of gliomas. Future research should focus on combining CIN-targeted therapies with immune modulation and personalized medicine to enhance patient outcomes.
Identifiants
pubmed: 39227895
doi: 10.1186/s40001-024-02043-8
pii: 10.1186/s40001-024-02043-8
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
451Informations de copyright
© 2024. The Author(s).
Références
He Z, Wilson A, Rich F, Kenwright D, Stevens A, Low YS, Thunders M. Chromosomal instability and its effect on cell lines. Cancer Rep. 2023;6(6):e1822. https://doi.org/10.1002/cnr2.1822 .
doi: 10.1002/cnr2.1822
Drews RM, Hernando B, Tarabichi M, Haase K, Lesluyes T, Smith PS, Morrill Gavarró L, Couturier DL, Liu L, Schneider M, Brenton JD, Van Loo P, Macintyre G, Markowetz F. A pan-cancer compendium of chromosomal instability. Nature. 2022;606(7916):976–83. https://doi.org/10.1038/s41586-022-04789-9 .
doi: 10.1038/s41586-022-04789-9
pubmed: 35705807
pmcid: 7613102
Langie SA, Koppen G, Desaulniers D, Al-Mulla F, Al-Temaimi R, Amedei A, Azqueta A, Bisson WH, Brown DG, Brunborg G, Charles AK, Chen T, Colacci A, Darroudi F, Forte S, Gonzalez L, Hamid RA, Knudsen LE, Leyns L, de Cerain L, Salsamendi A, Collins AR. Causes of genome instability: the effect of low dose chemical exposures in modern society. Carcinogenesis. 2015;36(Suppl1):S61–88. https://doi.org/10.1093/carcin/bgv031 .
doi: 10.1093/carcin/bgv031
pubmed: 26106144
pmcid: 4565613
Vias M, Morrill Gavarró L, Sauer CM, Sanders DA, Piskorz AM, Couturier DL, Ballereau S, Hernando B, Schneider MP, Hall J, Correia-Martins F, Markowetz F, Macintyre G, Brenton JD. High-grade serous ovarian carcinoma organoids as models of chromosomal instability. Elife. 2023;11(12): e83867. https://doi.org/10.7554/eLife.83867 .
doi: 10.7554/eLife.83867
Richardson TE, Walker JM, Abdullah KG, McBrayer SK, Viapiano MS, Mussa ZM, Tsankova NM, Snuderl M, Hatanpaa KJ. Chromosomal instability in adult-type diffuse gliomas. Acta Neuropathol Commun. 2022;10(1):115. https://doi.org/10.1186/s40478-022-01420-w .
doi: 10.1186/s40478-022-01420-w
pubmed: 35978439
pmcid: 9386991
Maimaiti A, Aili Y, Turhon M, Kadeer K, Aikelamu P, Wang Z, Niu W, Aisha M, Kasimu M, Wang Y, Wang Z. Modification patterns of DNA methylation-related lncRNAs regulating genomic instability for improving the clinical outcomes and tumour microenvironment characterisation of lower-grade gliomas. Front Mol Biosci. 2022;10(9): 844973. https://doi.org/10.3389/fmolb.2022.844973.PMID:35359593;PMCID:PMC8960387 .
doi: 10.3389/fmolb.2022.844973.PMID:35359593;PMCID:PMC8960387
Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, Li X, Babur O, Hsu TK, Lichtarge O, Weinstein JN, Akbani R, Wheeler DA. Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas. Cell Rep. 2019;28(5):1370-1384.e5. https://doi.org/10.1016/j.celrep.2019.07.001 .
doi: 10.1016/j.celrep.2019.07.001
pubmed: 31365877
pmcid: 7546539
Rieckhoff J, Meyer F, Classen S, Zielinski A, Riepen B, Wikman H, Petersen C, Rothkamm K, Borgmann K, Parplys AC. Exploiting chromosomal instability of PTEN-deficient triple-negative breast cancer cell lines for the sensitization against PARP1 inhibition in a replication-dependent manner. Cancers. 2020;12(10):2809. https://doi.org/10.3390/cancers12102809 .
doi: 10.3390/cancers12102809
pubmed: 33003585
pmcid: 7601067
Hisamatsu Y, Oki E, Otsu H, Ando K, Saeki H, Tokunaga E, Aishima S, Morita M, Oda Y, Maehara Y. Effect of EGFR and p-AKT overexpression on chromosomal instability in gastric cancer. Ann Surg Oncol. 2016;23(6):1986–92. https://doi.org/10.1245/s10434-016-5097-3 .
doi: 10.1245/s10434-016-5097-3
pubmed: 26847684
Thompson LL, Jeusset LM, Lepage CC, McManus KJ. Evolving therapeutic strategies to exploit chromosome instability in cancer. Cancers. 2017;9(11):151. https://doi.org/10.3390/cancers9110151 .
doi: 10.3390/cancers9110151
pubmed: 29104272
pmcid: 5704169
Sahajpal NS, Mondal AK, Vashisht A, et al. Optical genome mapping: integrating structural variations for precise homologous recombination deficiency score calculation. Genes. 2023;14(9):1683. https://doi.org/10.3390/genes14091683 .
doi: 10.3390/genes14091683
pubmed: 37761823
pmcid: 10530691
Bakhoum SF, Cantley LC. The multifaceted role of chromosomal instability in cancer and its microenvironment. Cell. 2018;174(6):1347–60. https://doi.org/10.1016/j.cell.2018.08.027 .
doi: 10.1016/j.cell.2018.08.027
pubmed: 30193109
pmcid: 6136429
Boveri T. Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. J Cell Sci. 2008;121(1):1–84. https://doi.org/10.1242/jcs.025742 .
doi: 10.1242/jcs.025742
pubmed: 18089652
von Hansemann D. Über asymmetrische Zellteilung in Epithelkrebsen und deren biologische Bedeutung. Virchows Arch Patholog Anat. 1890;119:299–326.
doi: 10.1007/BF01882039
Gollin SM. Mechanisms leading to chromosomal instability. Semin Cancer Biol. 2005;15:33–42. https://doi.org/10.1016/j.semcancer.2004.09.004 .
doi: 10.1016/j.semcancer.2004.09.004
pubmed: 15613286
McGranahan N, Burrell RA, Endesfelder D, Novelli MR, Swanton C. Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep. 2012;13:528–38. https://doi.org/10.1038/embor.2012.61 .
doi: 10.1038/embor.2012.61
pubmed: 22595889
pmcid: 3367245
Geigl JB, Obenauf AC, Schwarzbraun T, Speicher MR. Defining chromosomal instability. Trends Genet. 2008;24:64–9. https://doi.org/10.1016/j.tig.2007.11.006 .
doi: 10.1016/j.tig.2007.11.006
pubmed: 18192061
Vishwakarma R, McManus KJ. Chromosome instability; implications in cancer development, progression, and clinical outcomes. Cancers (Basel). 2020. https://doi.org/10.3390/cancers12040824 .
doi: 10.3390/cancers12040824
pubmed: 32235397
Paulsson K, Johansson B. High hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2009;48:637–60. https://doi.org/10.1002/gcc.20671 .
doi: 10.1002/gcc.20671
pubmed: 19415723
Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994;145:1175–90.
pubmed: 7977648
pmcid: 1887413
Patterson D. Molecular genetic analysis of down syndrome. Hum Genet. 2009;126:195–214. https://doi.org/10.1007/s00439-009-0696-8 .
doi: 10.1007/s00439-009-0696-8
pubmed: 19526251
Crasta K, Ganem NJ, Dagher R, et al. DNA breaks and chromosome pulverization from errors in mitosis. Nature. 2012;482:53–8.
doi: 10.1038/nature10802
pubmed: 22258507
pmcid: 3271137
Karcher S, Steiner HH, Ahmadi R, et al. Different angiogenic phenotypes in primary and secondary glioblastomas. Int J Cancer. 2006;118:2182–9.
doi: 10.1002/ijc.21648
pubmed: 16331629
Dokic I, Mairani A, Brons S, et al. High resistance to X-rays and therapeutic carbon ions in glioblastoma cells bearing dysfunctional ATM associates with intrinsic chromosomal instability. Int J Radiat Biol. 2015;91:157–65.
doi: 10.3109/09553002.2014.937511
pubmed: 24991884
Bochtler T, Kartal-Kaess M, Granzow M, et al. Micronucleus formation in human cancer cells is biased by chromosome size. Genes Chromosomes Cancer. 2019;58:392–5. https://doi.org/10.1002/gcc.22707 .
doi: 10.1002/gcc.22707
pubmed: 30411433
Drpic D, Almeida AC, Aguiar P, et al. Chromosome segregation is biased by kinetochore size. Curr Biol. 2018;28:1344–56.
doi: 10.1016/j.cub.2018.03.023
pubmed: 29706521
pmcid: 5954971
Cai H. Chromothripsis DB: a curated database for the documentation, visualization, and mining of chromothripsis data. Methods Mol Biol. 2018;1769:279–89.
doi: 10.1007/978-1-4939-7780-2_18
pubmed: 29564831
Duvuru S, Sanker V, Jain S, Sunil Kumar BS, Manoj Kumar M, Gupta U. A rare case of intra-parenchymal meningioma in a female patient who presented with seizures: a case report. Clin Case Rep. 2023;11: e7927. https://doi.org/10.1002/ccr3.7927 .
doi: 10.1002/ccr3.7927
pubmed: 37736479
pmcid: 10509343
van Tilborg AA, Al Allak B, Velthuizen SC, et al. Chromosomal instability in meningiomas. J Neuropathol Exp Neurol. 2005;64(4):312–22. https://doi.org/10.1093/jnen/64.4.312 .
doi: 10.1093/jnen/64.4.312
pubmed: 15835267
D’Assoro AB, Lingle WL, Salisbury JL. Centrosome amplification and the development of cancer. Oncogene. 2002;21:6146–53.
doi: 10.1038/sj.onc.1205772
pubmed: 12214243
Doxsey S. Duplicating dangerously: linking centrosome duplication and aneuploidy. Mol Cell. 2002;10:439–40.
doi: 10.1016/S1097-2765(02)00654-8
pubmed: 12408813
Kawamura K, Izumi H, Ma Z, Ikeda R, Moriyama M, Tanaka T, Nojima T, Levin LS, Fujikawa-Yamamoto K, Suzuki K, Fukasawa K. Induction of centrosome amplification and chromosome instability in human bladder cancer cells by p53 mutation and cyclin E overexpression. Cancer Res. 2004;64:4800–9.
doi: 10.1158/0008-5472.CAN-03-3908
pubmed: 15256449
Doxsey S. Re-evaluating centrosome function. Nat Rev Mol Cell Biol. 2001;2:688–98.
doi: 10.1038/35089575
pubmed: 11533726
Fukasawa K. Introduction. Centrosome. Oncogene. 2002;21:6140–5.
doi: 10.1038/sj.onc.1205771
pubmed: 12214242
Squatrito M, Brennan CW, Helmy K, Huse JT, Petrini JH, Holland EC. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell. 2010;18:619–29.
doi: 10.1016/j.ccr.2010.10.034
pubmed: 21156285
Golding SE, Rosenberg E, Valerie N, Hussaini I, FrigerioM Cockcroft XF, et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther. 2009;8:2894–902.
doi: 10.1158/1535-7163.MCT-09-0519
pubmed: 19808981
pmcid: 2761990
Golding SE, Rosenberg E, Khalil A, McEwen A, Holmes M, Neill S, et al. Double strand break repair by homologous recombination is regulated by cell cycle-independent signaling via ATM in human glioma cells. J Biol Chem. 2004;279:15402–10.
doi: 10.1074/jbc.M314191200
pubmed: 14744854
La Torre D, de Divitiis O, Conti A, et al. Expression of telomeric repeat binding factor-1 in astroglial brain tumors. Neurosurgery. 2005;56:802–10.
doi: 10.1227/01.NEU.0000156468.41461.6F
pubmed: 15792519
Gisselsson D, Jonson T, Petersen A, et al. Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. Proc Natl Acad Sci USA. 2001;98:12683–8.
doi: 10.1073/pnas.211357798
pubmed: 11675499
pmcid: 60114
Hande MP, Samper E, Lansdorp P, Blasco MA. Telomere length dynamics and chromosomal instability in cells derived from telomerase null mice. J Cell Biol. 1999;144:589–601.
doi: 10.1083/jcb.144.4.589
pubmed: 10037783
pmcid: 2132934
Maser RS, DePinho RA. Connecting chromosomes, crisis, and cancer. Science. 2002;297:565–9.
doi: 10.1126/science.297.5581.565
pubmed: 12142527
Rudolph KL, Chang S, Lee HW, et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell. 1999;96(5):701–12.
doi: 10.1016/S0092-8674(00)80580-2
pubmed: 10089885
Chin L, Artandi SE, Shen Q, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell. 1999;97:527–38.
doi: 10.1016/S0092-8674(00)80762-X
pubmed: 10338216
Hiraga S, Ohnishi T, Izumoto S, et al. Telomerase activity and alterations in telomere length in human brain tumors. Cancer Res. 1998;58:2117–25.
pubmed: 9605755
Le S, Zhu JJ, Anthony DC, Greider CW, Black PM. Telomerase activity in human gliomas. Neurosurgery. 1998;42(5):1120–4.
doi: 10.1097/00006123-199805000-00099
pubmed: 9588558
Bignold LP, Coghlan BL, Jersmann HP. Hansemann, Boveri, chromosomes and the gametogenesis-related theories of tumours. Cell Biol Int. 2006;30:640–4. https://doi.org/10.1016/j.cellbi.2006.04.002 .
doi: 10.1016/j.cellbi.2006.04.002
pubmed: 16753311
Friedlander M. Centrioles and centrospheres in giant cells of human gliomas. J Submicrosc Cytol. 1982;14:401–6.
pubmed: 7077718
Mittal K, Kaur J, Jaczko M, Wei G, Toss MS, Rakha EA, Janssen EAM, Søiland H, Kucuk O, Reid MD, Gupta MV, Aneja R. Centrosome amplification: a quantifiable cancer cell trait with prognostic value in solid malignancies. Cancer Metastasis Rev. 2021;40(1):319–39. https://doi.org/10.1007/s10555-020-09937-z .
doi: 10.1007/s10555-020-09937-z
pubmed: 33106971
Levine MS, Bakker B, Boeckx B, Moyett J, Lu J, Vitre B, Spierings DC, Lansdorp PM, Cleveland DW, Lambrechts D, Foijer F, Holland AJ. Centrosome amplification is sufficient to promote spontaneous tumorigenesis in mammals. Dev Cell. 2017;40(3):313-322.e5. https://doi.org/10.1016/j.devcel.2016.12.022 .
doi: 10.1016/j.devcel.2016.12.022
pubmed: 28132847
pmcid: 5296221
Coumar MS, Cheung CH, Chang JY, Hsieh HP. Advances in Aurora kinase inhibitor patents. Expert Opin Ther Pat. 2009;19:321–56. https://doi.org/10.1517/13543770802646949 .
doi: 10.1517/13543770802646949
pubmed: 19441907
Cheung CH, Coumar MS, Hsieh HP, Chang JY. Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs. 2009;18:379–98. https://doi.org/10.1517/13543780902806392 .
doi: 10.1517/13543780902806392
pubmed: 19335272
Kollareddy M, Dzubak P, Zheleva D, Hajduch M. Aurora kinases: structure, functions and their association with cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008;152:27–33.
doi: 10.5507/bp.2008.004
pubmed: 18795071
Rulseh AM, Keller J, Klener J, Sroubek J, Dbalý V, Syrůček M, Tovaryš F, Vymazal J. Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields. World J Surg Oncol. 2012;10:220. https://doi.org/10.1186/1477-7819-10-220 .
doi: 10.1186/1477-7819-10-220
pubmed: 23095807
pmcid: 3514151
Ramos-Fresnedo A, Pullen MW, Perez-Vega C, Domingo RA, Akinduro OO, Almeida JP, Suarez-Meade P, Marenco-Hillembrand L, Jentoft ME, Bendok BR, Trifiletti DM, Chaichana KL, Porter AB, Quiñones-Hinojosa A, Burns TC, Kizilbash SH, Middlebrooks EH, Sherman WJ. The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study. J Neurooncol. 2022;157(1):177–85. https://doi.org/10.1007/s11060-022-03960-6 .
doi: 10.1007/s11060-022-03960-6
pubmed: 35175545
Luo S, Zhang Y, Jia Y, Zhang X. Comprehensive analysis of intratumoural heterogeneity of somatic copy number alterations in diffuse glioma reveals clonality-dependent prognostic patterns. Neuropathol Appl Neurobiol. 2022;48(6): e12831. https://doi.org/10.1111/nan.12831 .
doi: 10.1111/nan.12831
pubmed: 35767937
Oh S, Yeom J, Cho HJ, Kim J, Yoon S, Kim H, Sa JK, Ju S, Lee H, Oh MJ, Lee W, Kwon Y, Li H, Choi S, Han JH, Chang JH, Choi E, Kim J, Her N, Kim HS. Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wildtype glioblastoma with prognostic and therapeutic opportunities. Nat Commun. 2020;11(1):1–16. https://doi.org/10.1038/s41467-020-17139-y .
doi: 10.1038/s41467-020-17139-y
pubmed: 31911652
pmcid: 6946686
Raviram R, Raman A, Preissl S, Ning J, Wu S, Koga T, Zhang K, Brennan CW, Zhu C, Luebeck J, Van Deynze K, Han JY, Hou X, Ye Z, Mischel AK, Li YE, Fang R, Baback T, Mugford J, Han CZ, Chen CC. Integrated analysis of single-cell chromatin state and transcriptome identified common vulnerability despite glioblastoma heterogeneity. Proc Natl Acad Sci USA. 2023;120(20):e2210991120. https://doi.org/10.1073/pnas.2210991120 .
doi: 10.1073/pnas.2210991120
pubmed: 37155843
pmcid: 10194019
Cosper PF, Copeland SE, Tucker JB, Weaver BA. Chromosome missegregation as a modulator of radiation sensitivity. Sem Rad Oncol. 2022;32(1):54–63. https://doi.org/10.1016/j.semradonc.2021.09.002 .
doi: 10.1016/j.semradonc.2021.09.002
Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15(19):6002–7. https://doi.org/10.1158/1078-0432.CCR-09-0715 .
doi: 10.1158/1078-0432.CCR-09-0715
pubmed: 19755387
Körber V, Yang J, Barah P, Wu Y, Stichel D, Gu Z, Fletcher MNC, Jones D, Hentschel B, Lamszus K, Tonn JC, Schackert G, Sabel M, Felsberg J, Zacher A, Kaulich K, Hübschmann D, Herold-Mende C, von Deimling A, Weller M, Lichter P. Evolutionary trajectories of IDH
doi: 10.1016/j.ccell.2019.02.007
pubmed: 30905762
Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, Reed R, Nelson SF, Cloughesy TF, James CD, Rao PN, Mischel PS. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014;343(6166):72–6. https://doi.org/10.1126/science.1241328 .
doi: 10.1126/science.1241328
pubmed: 24310612
Barresi V, Simbolo M, Mafficini A, Martini M, Calicchia M, Piredda ML, Ciaparrone C, Bonizzato G, Ammendola S, Caffo M, Pinna G, Sala F, Lawlor RT, Ghimenton C, Scarpa A. IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation. Acta Neuropathol Commun. 2021;9(1):200. https://doi.org/10.1186/s40478-021-01304-5 .
doi: 10.1186/s40478-021-01304-5
pubmed: 34952640
pmcid: 8709962
Hsu EJ, Thomas J, Maher EA, et al. Impact of CDKN2A/B, MTAP, and TERT genetic alterations on survival in IDH Wild Type glioblastomas. Discov Onc. 2022;13:126. https://doi.org/10.1007/s12672-022-00590-2 .
doi: 10.1007/s12672-022-00590-2
Esileanu CMS, Dirven L, Wijnenga MMJ, Koekkoek JAF, Vincent AJPE, Dubbink HJ, Atmodimedjo PN, Kros JM, van Duinen SG, Smits M, Taphoorn MJB, French PJ, van den Bent MJ. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro-oncology. 2020;22(4):515–23. https://doi.org/10.1093/neuonc/noz200 .
doi: 10.1093/neuonc/noz200
Wong QH, Li KK, Wang W, Malta TM, Noushmehr H, Grabovska Y, Jones C, Chan AK, Kwan JS, Huang QJ, Wong GC, Li W, Liu X, Chen H, Chan DT, Mao Y, Zhang Z, Shi Z, Ng H. Molecular landscape of IDH-mutant primary astrocytoma grade IV/glioblastomas. Mod Pathol. 2021;34(7):1245–60. https://doi.org/10.1038/s41379-021-00778-x .
doi: 10.1038/s41379-021-00778-x
pubmed: 33692446
Kurdi M, Mulla N, Katib Y, Alsinani T, Hakamy S, Addas MJB, Malibary H, Halawa TF, Farhan SM, Faizo E, Baeesa S. The cancer driver genes IDH1 and IDH2 and CD204 in WHO-grade 4 astrocytoma: crosstalk between cancer metabolism and tumour associated macrophage recruitment in tumour microenvironment. Biologics. 2023;17:15–22. https://doi.org/10.2147/BTT.S394556 .
doi: 10.2147/BTT.S394556
pubmed: 36778762
pmcid: 9912343
Bledea R, Vasudevaraja V, Patel S, Stafford J, Serrano J, Esposito G, Tredwin LM, Goodman N, Kloetgen A, Golfinos JG, Zagzag D. Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers. Sci Rep. 2019;9(1):1–12. https://doi.org/10.1038/s41598-019-53262-7 .
doi: 10.1038/s41598-019-53262-7
Suwala AK, Stichel D, Schrimpf D, Kloor M, Wefers AK, Reinhardt A, Maas SLN, Kratz CP, Schweizer L, Hasselblatt M, Snuderl M, Abedalthagafi MSJ, Abdullaev Z, Monoranu CM, Bergmann M, Pekrun A, Freyschlag C, Aronica E, Kramm CM, Hinz F, Reuss DE. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. Acta Neuropathol. 2021;141(1):85–100. https://doi.org/10.1007/s00401-020-02243-6 .
doi: 10.1007/s00401-020-02243-6
pubmed: 33216206
Liu Y, Sathe AA, Abdullah KG, et al. Global DNA methylation profiling reveals chromosomal instability in IDH-mutant astrocytomas. Acta Neuropathol Commun. 2022;10:32. https://doi.org/10.1186/s40478-022-01339-2 .
doi: 10.1186/s40478-022-01339-2
pubmed: 35264242
pmcid: 8908645
Hu Y, Ru N, Xiao H, Chaturbedi A, Hoa NT, Tian XJ, Zhang H, Ke C, Yan F, Nelson J, Li Z, Gramer R, Yu L, Siegel E, Zhang X, Jia Z, Jadus MR, Limoli CL, Linskey ME, Xing J, Zhou YH. Tumor-specific chromosome mis-segregation controls cancer plasticity by maintaining tumor heterogeneity. PloS one. 2013;8(11):e80898. https://doi.org/10.1371/journal.pone.0080898 .
doi: 10.1371/journal.pone.0080898
pubmed: 24282558
pmcid: 3839911
Wei Y, Li G, Feng J, et al. Stalled oligodendrocyte differentiation in IDH-mutant gliomas. Genome Med. 2023;15:24. https://doi.org/10.1186/s13073-023-01175-6 .
doi: 10.1186/s13073-023-01175-6
pubmed: 37055795
pmcid: 10103394
Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G, Perry A, Giannini C, Tihan T, Berger MS, Wiemels JL, Bracci PM, Eckel-Passow JE, Lachance DH, Clarke J, Taylor JW, Wrensch MR. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol. 2017;133(6):1001–16. https://doi.org/10.1007/s00401-017-1690-1 .
doi: 10.1007/s00401-017-1690-1
pubmed: 28255664
pmcid: 5432658
Fukuoka K, Mamatjan Y, Ryall S, Komosa M, Bennett J, Zapotocky M, Keith J, Myrehaug S, Hazrati LN, Aldape K, Laperriere N, Bouffet E, Tabori U, Hawkins C. BRAF V600E mutant oligodendroglioma-like tumors with chromosomal instability in adolescents and young adults. Brain Pathol. 2020;30(3):515–23. https://doi.org/10.1111/bpa.12799 .
doi: 10.1111/bpa.12799
pubmed: 31630459
Nigro JM, Takahashi MA, Ginzinger DG, Law M, Passe S, Jenkins RB, Aldape K. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol. 2001;158(4):1253–62. https://doi.org/10.1016/S0002-9440(10)64076-X .
doi: 10.1016/S0002-9440(10)64076-X
pubmed: 11290543
pmcid: 1891922
Lassaletta A, Zapotocky M, Mistry M, Ramaswamy V, Honnorat M, Krishnatry R, Guerreiro Stucklin A, Zhukova N, Arnoldo A, Ryall S, Ling C, McKeown T, Loukides J, Cruz O, de Torres C, Ho CY, Packer RJ, Tatevossian R, Qaddoumi I, Harreld JH, Tabori U. Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol. 2017;35(25):2934–41. https://doi.org/10.1200/JCO.2016.71.8726 .
doi: 10.1200/JCO.2016.71.8726
pubmed: 28727518
pmcid: 5791837
Sahm F, Schrimpf D, Jones DT, Meyer J, Kratz A, Reuss D, Capper D, Koelsche C, Korshunov A, Wiestler B, Buchhalter I, Milde T, Selt F, Sturm D, Kool M, Hummel M, Bewerunge-Hudler M, Mawrin C, Schüller U, Jungk C, von Deimling A. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 2016;131(6):903–10. https://doi.org/10.1007/s00401-015-1519-8 .
doi: 10.1007/s00401-015-1519-8
pubmed: 26671409
Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, Orisme W, Punchihewa C, Parker M, Qaddoumi I, Boop FA, Lu C, Kandoth C, Ding L, Lee R, Huether R, Chen X, Hedlund E, Nagahawatte P, Rusch M, St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013;45(6):602–12. https://doi.org/10.1038/ng.2611 .
doi: 10.1038/ng.2611
pubmed: 23583981
pmcid: 3727232
Zhang H, Liu K, Ba R, Zhang Z, Zhang Y, Chen Y, Gu W, Shen Z, Shu Q, Fu J, Wu D. Histological and molecular classifications of pediatric glioma with time-dependent diffusion MRI-based microstructural mapping. Neuro Oncol. 2023;25(6):1146–56. https://doi.org/10.1093/neuonc/noad003 .
doi: 10.1093/neuonc/noad003
pubmed: 36617263
pmcid: 10237431
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–51. https://doi.org/10.1093/neuonc/noab106 .
doi: 10.1093/neuonc/noab106
pubmed: 34185076
pmcid: 8328013
Wang AC, Jones DTW, Abecassis IJ, Cole BL, Leary SES, Lockwood CM, Chavez L, Capper D, Korshunov A, Fallah A, Wang S, Ene C, Olson JM, Geyer JR, Holland EC, Lee A, Ellenbogen RG, Ojemann JG. Desmoplastic infantile ganglioglioma/astrocytoma (DIG/DIA) are distinct entities with frequent BRAFV600 mutations. Mol Cancer Res. 2018;16(10):1491–8. https://doi.org/10.1158/1541-7786.MCR-17-0507 .
doi: 10.1158/1541-7786.MCR-17-0507
pubmed: 30006355
pmcid: 7269191
Sugiyama K, Arita K, Shima T, Nakaoka M, Matsuoka T, Taniguchi E, Okamura T, Yamasaki H, Kajiwara Y, Kurisu K. Good clinical course in infants with desmoplastic cerebral neuroepithelial tumor treated by surgery alone. J Neurooncol. 2002;59(1):63–9. https://doi.org/10.1023/a:1016309813752 .
doi: 10.1023/a:1016309813752
pubmed: 12222839
Cerdá-Nicolás M, Lopez-Gines C, Gil-Benso R, et al. Desmoplastic infantile ganglioglioma: Morphological, immunohistochemical and genetic features. Histopathology. 2006;81:617–21.
Lönnrot K, Terho M, Kähärä V, et al. Desmoplastic infantile ganglioglioma: novel aspects in clinical presentation and genetics. Surg Neurol. 2007;68:304–8.
doi: 10.1016/j.surneu.2006.11.043
pubmed: 17719974
Park JP, Dossu JR, Rhodes CH. Telomere associations in desmoplastic infantile ganglioglioma. Cancer Genet Cytogenet. 1996;92:4–7.
doi: 10.1016/S0165-4608(96)00166-5
pubmed: 8956861
Kros JM, Delwel EJ, de Jong TH, et al. Desmoplastic infantile astrocytoma and ganglioglioma: a search for genomic characteristics. Acta Neuropathol. 2002;104:144–8.
doi: 10.1007/s00401-002-0534-8
pubmed: 12111357
Gessi M, Zur Mühlen A, Hammes J, Waha A, Denkhaus D, Pietsch T. Genome-wide DNA copy number analysis of desmoplastic infantile astrocytomas and desmoplastic infantile gangliogliomas. J Neuropathol Exp Neurol. 2013;72(9):807–15. https://doi.org/10.1097/NEN.0b013e3182a033a0 .
doi: 10.1097/NEN.0b013e3182a033a0
pubmed: 23965740
Hernández-Hernández A, López-Santaella T, Torres-Caballero A, Serrato A, Torres-Flores U, Montesinos-Valencia D, Chico-Ponce de León F, González-Carranza V, Torres-García S, Rebollar-Vega R, De la Rosa-Velázquez IA, Ortiz R, Pérez-Ramírez M, García-Hernández N, García-Méndez A, Arenas-Huertero F. The transcriptomic landscape of pediatric astrocytoma. Int J Mol Sci. 2022;23(20):12696. https://doi.org/10.3390/ijms232012696 .
doi: 10.3390/ijms232012696
pubmed: 36293551
pmcid: 9604090
López GY, Perry A, Harding B, Li M, Santi M. CDKN2A/B loss is associated with anaplastic transformation in a case of NTRK2 fusion-positive pilocytic astrocytoma. Neuropathol Appl Neurobiol. 2019;45(2):174–8. https://doi.org/10.1111/nan.12503 .
doi: 10.1111/nan.12503
pubmed: 29804288
Grau E, Balaguer J, Canete A, et al. Subtelomeric analysis of pediatric astrocytoma: subchromosomal instability is a distinctive feature of pleomorphic xanthoastrocytoma. J Neurooncol. 2009;93:175–82. https://doi.org/10.1007/s11060-008-9763-6 .
doi: 10.1007/s11060-008-9763-6
pubmed: 19099200
Rickert CH, Sträter R, Kaatsch P, Wassmann H, Jürgens H, Dockhorn-Dworniczak B, Paulus W. Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. Am J Pathol. 2001;158(4):1525–32. https://doi.org/10.1016/S0002-9440(10)64103-X .
doi: 10.1016/S0002-9440(10)64103-X
pubmed: 11290570
pmcid: 1891902
Yang W, Porras JL, Khalafallah AM, Sun Y, Bettegowda A, Mukherjee D. Comparison of adult and pediatric pilocytic astrocytomas using competing risk analysis: a population-based study. Clin Neurol Neurosurg. 2022;1(212):107084–94.
doi: 10.1016/j.clineuro.2021.107084
Tripathi R, Modur V, Senovilla L, Kroemer G, Komurov K. Suppression of tumor antigen presentation during aneuploid tumor evolution contributes to immune evasion. Oncoimmunology. 2019;8(11):1657374. https://doi.org/10.1080/2162402X.2019.1657374 .
doi: 10.1080/2162402X.2019.1657374
pubmed: 31646083
pmcid: 6791449
Levine AB, Nobre L, Das A, et al. Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment. Nat Commun. 2024;15(1):5790. https://doi.org/10.1038/s41467-024-49595-1 .
doi: 10.1038/s41467-024-49595-1
pubmed: 38987542
pmcid: 11237052
Shalaby A, Shalaby O, Abdullah H, Boulassel MR, Arafa M. Correlation of PD-L1 expression with different clinico-pathological and immunohistochemical features of ovarian surface epithelial tumors. Clin Transl Oncol. 2024. https://doi.org/10.1007/s12094-024-03613-2 .
doi: 10.1007/s12094-024-03613-2
pubmed: 39090421
Zhao M, Wang Q, Wang Q, Jia P, Zhao Z. Computational tools for copy number variation (CNV) detection using next-generation sequencing data: features andperspectives. BMC Bioinf. 2013;14:S1. https://doi.org/10.1186/1471-2105-14-S11-S1 .
doi: 10.1186/1471-2105-14-S11-S1
Bhuvaneshwar K, Belouali A, Singh V, et al. G-DOC Plus: an integrative bioinformatics platform for precision medicine. BMC Bioinf. 2016;17:193. https://doi.org/10.1186/s12859-016-1010-0 .
doi: 10.1186/s12859-016-1010-0
Song L, Bhuvaneshwar K, Wang Y, Feng Y, Shih I-M, Madhavan S, Gusev Y. CINdex: a bioconductor package for analysis of chromosome instability in DNA copy number data. Cancer Inf. 2017;16:1176935117746637. https://doi.org/10.1177/1176935117746637 .
doi: 10.1177/1176935117746637
Gao R, Fu ZC, Li X, Wang Y, Wei J, Li G, Wang L, Wu J, Huang X, Yang L, Chen J. Genomic and transcriptomic analyses of prime editing guide rna-independent off-target effects by prime editors. CRISPR J. 2022;5(2):276–93. https://doi.org/10.1089/crispr.2021.0080 .
doi: 10.1089/crispr.2021.0080
pubmed: 35294852
Liang J, Lv X, Lu C, Ye X, Chen X, Fu J, Luo C, Zhao Y. Prognostic factors of patients with gliomas—an analysis on 335 patients with Glioblastoma and other forms of Gliomas. BMC Cancer. 2020. https://doi.org/10.1186/s12885-019-6511-6 .
doi: 10.1186/s12885-019-6511-6
pubmed: 33243205
pmcid: 7690101
Goldbrunner R, Ruge M, Kocher M, Lucas CW. The treatment of gliomas in adulthood. Dtsch Arztebl Int. 2018;115(20–21):356–64. https://doi.org/10.3238/arztebl.2018.0356 .
doi: 10.3238/arztebl.2018.0356
pubmed: 29914619
pmcid: 6172648
Hong C, Schubert M, Tijhuis AE, Requesens M, Roorda M, Ruiz LA, Bakker PL, Pieters W, Chen M, Wardenaar R, Spierings DC, De Bruyn M, Van Vugt MA, Foijer F. CGAS–STING drives the IL-6-dependent survival of chromosomally instable cancers. Nature. 2022;607(7918):366–73. https://doi.org/10.1038/s41586-022-04847-2 .
doi: 10.1038/s41586-022-04847-2
pubmed: 35705809
Lombardi G, Barresi V, Indraccolo S, Simbolo M, Fassan M, Mandruzzato S, Simonelli M, Caccese M, Pizzi M, Fassina A, Padovan M, Masetto E, Gardiman MP, Bonavina MG, Caffo M, Persico P, Chioffi F, Denaro L, Dei Tos AP, Scarpa A, Zagonel V. Pembrolizumab activity in recurrent high-grade gliomas with partial or complete loss of mismatch repair protein expression: a monocentric, observational and prospective pilot study. Cancers. 2020;12(8):2283. https://doi.org/10.3390/cancers12082283 .
doi: 10.3390/cancers12082283
pubmed: 32823925
pmcid: 7464918
Wang Y, Drum DL, Sun R, Zhang Y, Chen F, Sun F, Dal E, Yu L, Jia J, Arya S, Jia L, Fan S, Isakoff SJ, Kehlmann AM, Dotti G, Liu F, Zheng H, Ferrone CR, Taghian AG, Wang X. Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment. Nat Commun. 2023;14(1):1–17. https://doi.org/10.1038/s41467-023-41282-x .
doi: 10.1038/s41467-023-41282-x
Eckerdt FD, Bell JB, Gonzalez C, Oh MS, Perez RE, Mazewski C, Fischietti M, Goldman S, Nakano I, Platanias LC. Combined PI3Kα-mTOR targeting of glioma stem cells. Sci Rep. 2020;10(1):1–11. https://doi.org/10.1038/s41598-020-78788-z .
doi: 10.1038/s41598-020-78788-z
Wenger A, Karlsson I, Kling T, Carén H. CRISPR-Cas9 knockout screen identifies novel treatment targets in childhood high-grade glioma. Clin Epigenetics. 2023;15(1):80. https://doi.org/10.1186/s13148-023-01498-6 .
doi: 10.1186/s13148-023-01498-6
pubmed: 37161535
pmcid: 10170782
Golas MM, Gunawan B, Cakir M, Cameron S, Enders C, Liersch T, Füzesi L, Sander B. Evolutionary patterns of chromosomal instability and mismatch repair deficiency in proximal and distal colorectal cancer. Colorectal Dis. 2022;24(2):157–76. https://doi.org/10.1111/codi.15946 .
doi: 10.1111/codi.15946
pubmed: 34623739
Ghosh D, Nandi S, Bhattacharjee S. Combination therapy to checkmate glioblastoma: clinical challenges and advances. Clin Transl Med. 2018;7(1):33. https://doi.org/10.1186/s40169-018-0211-8 .
doi: 10.1186/s40169-018-0211-8
pubmed: 30327965
pmcid: 6191404
Godek KM, Venere M, Wu Q, Mills KD, Hickey WF, Rich JN, Compton DA. Chromosomal instability affects the tumorigenicity of glioblastoma tumor-initiating cells. Cancer Discov. 2016;6(5):532–45. https://doi.org/10.1158/2159-8290.CD-15-1154 .
doi: 10.1158/2159-8290.CD-15-1154
pubmed: 27001151
pmcid: 4854766
Bakhoum SF, Landau DA. Chromosomal Instability as a Driver of Tumor Heterogeneity and Evolution. Cold Spring Harb Perspect Med. 2017;7(6):a029611. https://doi.org/10.1101/cshperspect.a029611 .
doi: 10.1101/cshperspect.a029611
pubmed: 28213433
pmcid: 5453382